Leite Katia R, Mitteldorf Cristina A, Camara-Lopes Luiz H
Laboratory of Surgical and Molecular Pathology, Syrian-Lebanese Hospital, Sao Paulo, SP, Brazil.
Int Braz J Urol. 2005 Mar-Apr;31(2):131-6. doi: 10.1590/s1677-55382005000200007.
To assess the incidence of diagnosis of high-grade intraepithelial neoplasia or prostate intraepithelial neoplasia (PIN), and atypical small gland proliferation (ASAP) at a uropathology reference center. To assess the indexes and findings on repeat biopsies.
Diagnoses of PIN, ASAP or PIN + ASAP established between January 1, 2001 and December 31, 2003 were searched in our database. We studied repeat biopsies performed up to August 31, 2004.
Of 1420 biopsies, ASAP was diagnosed in 26 (1.8%) patients, PIN in 142 (10%) and PIN + ASAP in 40 (2.8%). Repeat biopsies were performed in 98 patients, 16 (61.5%) with ASAP, 53 (37.3%) with PIN and 29 (72.5%) with PIN + ASAP. Carcinoma was diagnosed in 7 cases (43.8%) following a diagnosis of ASAP, 12 (41.4%) of PIN + ASAP and 7 (13.2%) of PIN. The mean interval between repeat biopsies was 299.6 days. There was no difference between groups where cancer was or was not diagnosed on repeat biopsy in relation to age and serum PSA levels.
Despite explicit recommendations of repeat biopsy on pathology reports and the high incidence of adenocarcinoma on repeat biopsy, re-intervention rates following a diagnosis of PIN, ASAP, PIN + ASAP are low in our setting. The diagnosis that most frequently led to repeat biopsy was PIN + ASAP. Adenocarcinoma was most often diagnosed after the initial diagnosis of ASAP.
评估在一家泌尿病理学参考中心高级别上皮内瘤变或前列腺上皮内瘤变(PIN)以及非典型小腺泡增生(ASAP)的诊断发生率。评估重复活检的指标及结果。
检索我们数据库中2001年1月1日至2003年12月31日期间确诊的PIN、ASAP或PIN+ASAP病例。我们研究了截至2004年8月31日所做的重复活检。
在1420例活检中,26例(1.8%)患者被诊断为ASAP,142例(10%)为PIN,40例(2.8%)为PIN+ASAP。98例患者接受了重复活检,其中16例(61.5%)为ASAP,53例(37.3%)为PIN,29例(72.5%)为PIN+ASAP。在诊断为ASAP后,7例(43.8%)被诊断为癌;诊断为PIN+ASAP后,12例(41.4%)被诊断为癌;诊断为PIN后,7例(13.2%)被诊断为癌。重复活检的平均间隔时间为299.6天。在重复活检时是否诊断出癌症的两组患者之间,年龄和血清前列腺特异抗原(PSA)水平并无差异。
尽管病理报告中有明确的重复活检建议,且重复活检时腺癌的发生率较高,但在我们的研究环境中,诊断为PIN、ASAP、PIN+ASAP后的再次干预率较低。最常导致重复活检的诊断是PIN+ASAP。腺癌最常于最初诊断为ASAP后被诊断出来。